-
体外受精-胚胎移植(in vitro fertilization-embryo transfer,IVF-ET)治疗的预后取决于卵巢反应性和卵母细胞质量,这两个因素既决定了产生优质胚胎的数量,也会影响最终的妊娠结局[1-2]。卵巢低反应(poor ovarian response, POR)是卵巢对促性腺激素(Gn)刺激反应不良的病理状态,占IVF治疗周期的9%~30%不等,主要表现为卵巢刺激周期发育的卵泡少、血雌激素峰值低、Gn用量多、周期取消率高、获卵数少和临床妊娠率低[3]。尽管使用了不同的治疗策略,但POR病人的临床妊娠率仍然很低。为此,临床上提出了多种治疗策略来改善这类问题。其中,生长激素(growth hormone, GH)被认为在生殖内分泌中发挥重要作用[4]。目前,GH辅助治疗已经取得较为广泛且深入的研究进展,然而临床结局优劣各异。有研究[5]表明,在POR人群中,合适的GH补充方案可显著提高IVF成功率。但亦有研究[6]提出,GH不能改善POR病人的妊娠结局。基于此,我们对POR病人的拮抗剂方案中GH联合治疗的疗效作一分析。现作报道。
-
回顾性分析2018年1月至2019年6月在我中心接受IVF-ET治疗并采用拮抗剂方案的POR病人176例,按照是否应用GH分为应用GH组(GH+组)84例和不应用GH组(GH-组)92例。2组病人年龄、不孕年限、体质量指数(BMI)、子宫内膜厚度、基础卵泡刺激素(follicle-stimulating hormone, FSH)水平、Gn时间、Gn剂量等差异均无统计学意义(P > 0.05)(见表 1),具有可比性。
分组 n 年龄/岁 男方年龄/岁 不孕时间/年 BMI/(kg/m2) 内膜厚度/mm 基础FSH/(pmol/L) Gn时间/d Gn剂量/支 GH+ 84 38.8±3.92 37.9±4.22 4.9±3.24 22.2±3.79 10.13±2.04 8.17±3.14 10.29±2.89 36.75±9.57 GH- 92 39.2±4.23 37.6±4.59 4.7±3.65 22.9±4.08 10.52±2.25 8.53±2.85 11.05±3.17 37.55±9.21 t — 0.65 0.45 0.38 1.18 1.20 0.80 1.66 0.56 P — > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 表 1 2组病人一般资料比较(x±s)
-
GH联合拮抗剂方案行促排卵,第1天开始,每日皮下注射1.33 mg(4 IU) GH(Norditropin pen, Novo Nordisk, 丹麦),直到人绒毛膜促性腺激素(hCG)日为止。hCG日后36~38 h取卵, 取卵日男方取精,采用密度梯度离心加上游法处理。IVF病人所得卵母细胞培养2~4 h加精;单精子显微注射病人卵母细胞培养4 h,行单精子显微注射操作。
-
使用Vitrolife培养液(Vitrolife, 瑞典)进行体外培养。加精后17~19 h记录受精情况。培养至第3、5、6天分别进行胚胎评级,之后移植、冷冻或废弃。
-
移植后给予黄体酮等黄体支持,移植后第14天检测血hCG,确定生化妊娠与否。移植后第35天,进行超声检查,确定是否临床妊娠。
-
比较2组获卵数、MⅡ卵率、正常受精率、第3天可移植胚胎率、第3天优质胚胎率、囊胚形成率、优质囊胚率、临床妊娠率、种植率等指标。
-
采用t检验和χ2检验。
-
GH+组获卵数、第3天可移植胚胎率、囊胚形成率、临床妊娠率、种植率均高于GH-组(P < 0.05~P < 0.01),2组MⅡ卵率、正常受精率、第3天优质胚胎率、优质囊胚率差异均无统计学意义(P > 0.05)(见表 2)。
分组 n 获卵数 MⅡ卵率 正常受精率 第3天可移植胚胎率 第3天优质胚胎率 囊胚形成率 优质囊胚率 临床妊娠率 种植率 GH+ 84 10.63±3.92 75.03(667/889) 77.65(587/756) 76.79(440/573) 19.20(110/573) 56.56(194/343) 24.35(47/193) 54.93(39/71) 34.81(47/135) GH- 92 7.76±2.23 73.94(525/710) 78.31(473/604) 71.40(327/458) 18.56(85/458) 48.45(125/258) 24.00(30/125) 38.67(29/75) 23.53(32/136) χ2 — 6.03* 0.24 0.09 3.88 0.07 3.89 0.01 3.88 4.18 P — < 0.01 > 0.05 > 0.05 < 0.05 > 0.05 < 0.05 > 0.05 < 0.05 < 0.05 *示t值 表 2 2组妊娠结局和妊娠相关指标比较(%)
生长激素联合拮抗剂方案对卵巢低反应人群IVF-ET妊娠结局的作用
Effect of growth hormone combined with antagonist regimen on pregnancy outcomes in IVF-ET patients with low ovarian response
-
摘要:
目的探讨卵巢低反应(poor ovarian response, POR)病人接受体外受精-胚胎移植(in vitro fertilization-embryo transfer,IVF-ET)治疗时,应用生长激素(growth hormone, GH)联合拮抗剂方案对妊娠结局的影响。 方法回顾性分析接受IVF-ET治疗并采用拮抗剂方案的POR病人176例临床资料,按照是否应用GH分为应用GH组(GH+组)84例和不应用GH组(GH-组)92例。比较2组获卵数、MⅡ卵率、正常受精率、第3天可移植胚胎率、第3天优质胚胎率、囊胚形成率、优质囊胚率、临床妊娠率、种植率等指标。 结果GH+组获卵数、第3天可移植胚胎率、囊胚形成率、临床妊娠率、种植率均高于GH-组(P < 0.05~P < 0.01),2组MⅡ卵率、正常受精率、第3天优质胚胎率、优质囊胚率差异均无统计学意义(P > 0.05)。 结论GH联合拮抗剂方案有助于改善POR人群IVF-ET妊娠结局。 Abstract:ObjectiveTo explore the effects of the growth hormone(GH) combined with antagonist regimen on pregnancy outcome in poor ovarian response(POR) patients treated with fertilization-embryo transfer(IVF-ET) in vitro. MethodsThe clinical data of 176 POR patients treated with IVF-ET were retrospectively analyzed, and the patients were divided into the GH group(GH+ group, 84 cases) and non-GH group(GH- group, 92 cases) according to whether GH was used or not. The egg number, MⅡ egg rate, normal fertilization rate, day 3 transferable embryo rate, day 3 high quality embryo rate, blastocyst formation rate, high quality blastocyst rate, clinical pregnancy rate and implantation rate were compared between two groups. ResultsThe egg number, daybryo rate, blastocyst formation rate, clinical pregnancy rate and implantation rate in GH+ group were higher than those in GH- group(P < 0.05 to P < 0.01).The differences of MⅡ egg rate, normal fertilization rate, high quality embryo rate on day 3 and high quality blastocyst rate between two groups were not statistically significant(P > 0.05). ConclusionsThe GH combined antagonist regimen is helpful for improving IVF-ET pregnancy outcomes in the POR patients. -
Key words:
- fertilization-embryo transfer /
- poor ovarian respone /
- growth hormone
-
表 1 2组病人一般资料比较(x±s)
分组 n 年龄/岁 男方年龄/岁 不孕时间/年 BMI/(kg/m2) 内膜厚度/mm 基础FSH/(pmol/L) Gn时间/d Gn剂量/支 GH+ 84 38.8±3.92 37.9±4.22 4.9±3.24 22.2±3.79 10.13±2.04 8.17±3.14 10.29±2.89 36.75±9.57 GH- 92 39.2±4.23 37.6±4.59 4.7±3.65 22.9±4.08 10.52±2.25 8.53±2.85 11.05±3.17 37.55±9.21 t — 0.65 0.45 0.38 1.18 1.20 0.80 1.66 0.56 P — > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 表 2 2组妊娠结局和妊娠相关指标比较(%)
分组 n 获卵数 MⅡ卵率 正常受精率 第3天可移植胚胎率 第3天优质胚胎率 囊胚形成率 优质囊胚率 临床妊娠率 种植率 GH+ 84 10.63±3.92 75.03(667/889) 77.65(587/756) 76.79(440/573) 19.20(110/573) 56.56(194/343) 24.35(47/193) 54.93(39/71) 34.81(47/135) GH- 92 7.76±2.23 73.94(525/710) 78.31(473/604) 71.40(327/458) 18.56(85/458) 48.45(125/258) 24.00(30/125) 38.67(29/75) 23.53(32/136) χ2 — 6.03* 0.24 0.09 3.88 0.07 3.89 0.01 3.88 4.18 P — < 0.01 > 0.05 > 0.05 < 0.05 > 0.05 < 0.05 > 0.05 < 0.05 < 0.05 *示t值 -
[1] DÍAZ-GIMENO P, HORCAJADAS JA, MARTÍNEZ-CONEJERO JA. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature[J]. Fertil Steril, 2011, 95(1): 50. doi: 10.1016/j.fertnstert.2010.04.063 [2] ACHACHE H, REVEL A. Endometrial receptivity markers, the journey to successful embryo implantation[J]. Hum Reprod Update, 2006, 12(6): 731. doi: 10.1093/humupd/dml004 [3] FERRARETTI AP, LA MARCA A, FAUSER BCJM. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria[J]. Hum Reprod, 2011, 26(7): 1616. doi: 10.1093/humrep/der092 [4] HULL KL, HARVEY S. Growth hormone: roles in female reproduction[J]. J Endocrinol, 2001, 168(1): 1. doi: 10.1677/joe.0.1680001 [5] LI XL, WANG L, LV F. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis[J]. Medicine, 2017, 96(12): 96. [6] HART ROGER J. Use of Growth Hormone in the IVF treatment of women with poor ovarian reserve[J]. Frontiers in Endocrinol, 2019, 24: 10. [7] NISHIYAMA K, SUGIMOTO T, KAJI H. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation[J]. Endocrinology, 1996, 137: 35. doi: 10.1210/endo.137.1.8536635 [8] HERRINGTON J, CARTER-SU C. Signaling pathways activated by the growth hormone receptor[J]. Trends Endocrinol Metab, 2001, 12(6): 252. doi: 10.1016/S1043-2760(01)00423-4 [9] HULL KL, HARVEY S. Growth hormone: roles in female reproduction[J]. J Endocrinol, 2001, 168(1): 1. doi: 10.1677/joe.0.1680001 [10] HOMBURG R, ESHEL A, ABDALLA HI. Growth hormone facilitates ovulation induction by gonadotrophins[J]. Clin Endocrinol(Oxf), 1988, 29(1): 113. doi: 10.1111/j.1365-2265.1988.tb00252.x [11] NAKAMURA E, OTSUKA F, INAGAKI K. Mutual regulation of growth hormone and bone morpho genetic protein system in steroidogenesis by rat granulosa cells[J]. Endocrinology, 2012(153): 469. [12] SLOT KA, KASTELIJN J, BACHELOT A. Reduced recruitment and survival of primordial and growing follicles in GH receptor-deficient mice[J]. Reproduction, 2006, 131(3): 525. doi: 10.1530/rep.1.00946 [13] BACHELOT A, MONGET P, IMBERT-BOLLORÉ P. Growth hormone is required for ovarian follicular growth[J]. Endocrinology, 2002, 143(10): 4104. doi: 10.1210/en.2002-220087 [14] YOSHIMURA Y, NAKAMURA Y, KOYAMA N. Effects of growth hormone on follicle growth, oocyte maturation, and ovarian steroidogenesis[J]. Fertil Steril, 1993, 59(4): 917. doi: 10.1016/S0015-0282(16)55882-8 [15] BEVERS MM, IZADYAR F. Role of growth hormone and growth hormone receptor in oocyte maturation[J]. Mol Cell Endocrinol, 2002, 197: 173. doi: 10.1016/S0303-7207(02)00270-8 [16] YUNGAI X, LI T. The effect of growth hormone on endometrial receptivity in mice[J]. J Med Forum, 2006, 27: 35. [17] AKMAN MA, ERDEN HF, TOSUN SB. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial[J]. Hum Reprod, 2001, 5: 868. [18] FOLCH J, RAMO'N JP, COCERO MJ. Exogenous growth hormone improves the number of transferable embryos in superovulated ewes[J]. Theriogenology, 2001, 55(9): 1777. doi: 10.1016/S0093-691X(01)00520-9 [19] MOREIRA F, BADINGA L, BURNLEY C. Bovine somatotropin increases embryonic development in superovulated cows and improves post-transfer pregnancy rates when given to lactating recipient cows[J]. Theriogenology, 2002, 57(4): 1371. doi: 10.1016/S0093-691X(01)00719-1 [20] LANZONE A, FORTINI A, FULGHESU AM. Growth hormone enhances estradiol production follicle-stimulating hormone-induced in the early stage of the follicular maturation[J]. Fertil Steril, 1996, 66(6): 948. doi: 10.1016/S0015-0282(16)58688-9 [21] SILVA JRV, FIGUEIREDO JR, VAN DEN HURK R. Involvement of growth hormone(GH) and insulin-likegrowth factor(IGF) system in ovarian folliculogenesis[J]. Theriogenology, 2009, 71(8): 1193. doi: 10.1016/j.theriogenology.2008.12.015 [22] KIAPEKOU E, LOUTRADIS D, DRAKAKIS P. Effects of GH and IGF-Ⅰ on the in vitro maturation of mouse oocytes[J]. Hormones, 2005, 4: 155. doi: 10.14310/horm.2002.11153 [23] YOVICH JL, STANGER JD. Growth hormone supplementation improves implantation and pregnancy productivity rates for poorprognosis patients undertaking IVF[J]. Reprod Biomed Online, 2010, 21: 37. doi: 10.1016/j.rbmo.2010.03.013 [24] KÖLLE S, STOJKOVIC M, REESE S. Effects of growth hormone on the ultrastructure of bovine preimplantation embryos[J]. Cell Tissue Res, 2004, 317: 101. [25] KIDSON A, RUBIO-POMAR FJ, VAN KNEGSEL A. Quality of porcine blastocysts produced in vitro in the presence or absence of GH[J]. Reproduction, 2004, 127(2): 165. doi: 10.1530/rep.1.00086 [26] YANG C, FENGHUA L. Effect of growth hormone on the endometrium receptivity in SD mice[J]. J Biomed Eng, 2012, 3: 1674. [27] 朱桂金, 徐蓓, 李舟. 孕酮调节子宫内膜的容受性[J]. 生殖医学杂志, 2013, 22(4): 272. doi: 10.3969/j.issn.1004-3845.2013.04.016 [28] SPILIOTIS BE. Growth hormone insufficiency and its impact on ovarian function[J]. Ann N Y Acad Sci, 2003, 997(1): 77. doi: 10.1196/annals.1290.009